Overview

CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer

Status:
Completed
Trial end date:
2003-10-01
Target enrollment:
Participant gender:
Summary
To determine the safety and efficacy of CPG 7909 Injection given with Herceptin to patients with metastatic breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Trastuzumab